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ABSTRACT 
 
Background: Secretion of cytokines and display of cytokine receptors have been reported in 
the orbital connective tissue in Graves’ orbitopathy (GO). Lacrimal glands are putative 
autoimmune targets, and changes in tear film and ocular surface have also been described. 
Our aim was to characterize the cytokine profile of tears in Graves’ patients with (GO) and 
without orbitopathy (GD). 
Methods: Tear samples were collected from 54 eyes of GO patients (age 43.4 ±15.2 years), 
18 eyes of GD patients (age 46.8±11.7 years), and 24 control eyes (age 38.6±13.8 years). 
Patients underwent ophthalmological examination including Clinical Activity Score (CAS). 
The level of interleukin (IL)-1, IL-6, IL-13, IL-17A, IL-18, Tumor Necrosis Factor- and 
RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted) as well as 
Plasminogen activator inhibitor-1 (PAI-1) were measured by multiplex bead array and  
release values were calculated.  
Results: The release of IL-1β, IL-6, IL-13, IL-17A, IL-18, TNF- and RANTES were 
significantly higher in GO patients compared to controls (p<0.05). There was a 2.5-fold 
increase of IL-6 release. No significant differences were found in cytokine release between 
the GO and GD groups. In the GO group, significant positive correlation was found between 
CAS and the release of IL-6 and PAI-1 into tears (r=0.27, p<0.05 and r=0.24, p<0.05, 
respectively). PAI-1 release was significantly higher in GO than in GD patients, and was 
increased in both the GD and GO groups compared to controls.  
Conclusions: Impaired cytokine balance has been observed in tears of GO patients. Secretion 
of IL-6 into tears might be a useful indicator of disease activity in GO. 
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INTRODUCTION 
 
Graves’ orbitopathy (GO) is an autoimmune disorder characterized by enlargement of 
extraocular muscles and increased volume in orbital connective tissues (1). Although GO is 
the most frequent extrathyroidal manifestation of Graves’ disease, Hashimoto’s thyroiditis can 
also be accompanied with orbitopathy (2). GO may also precede or follow the hyperthyroid 
phase of Graves’ disease without any clinical or biochemical evidence of thyroid dysfunction 
(3). Retrobulbar inflammation takes place in the orbital connective tissue and eye muscles; 
mononuclear cells, predominantly T lymphocytes and macrophages infiltrate the orbital tissue 
(4). Interaction between activated T lymphocytes and orbital fibroblasts results in the release 
of cytokines into orbital connective tissue (5). Increased expression of macrophage- derived 
cytokines Interleukin (IL)-1β, Tumor Necrosis Factor-α (TNFα) and IL-10 have been 
described in orbital tissues of GO patients (6). Several studies have also shown increased IL-6 
levels in the sera of GO patients (7, 8). Macrophage-derived cytokines play an important role 
in the pathogenesis of GO, and IL-1 and TNFα  stimulate Intercellular Adhesion Molecule 1 
(ICAM-1) expression and glycosaminoglycan (GAG) production of orbital fibroblasts (9). 
Orbital tissue remodeling in GO seems to be the result of cytokine dependent fibroblast 
activation and fibroblasts themselves also express high levels of T lymphocyte 
chemoattractants as RANTES (Regulated upon Activation, Normal T-cell Expressed, and 
Secreted) and IL-16 (10). A change in cytokine profile accompanies the phases of the disease, 
with Th1 cytokines predominating in the active phase, and Th2 cytokines in the late, fibrotic 
phase (11). 
Immune activity in orbitopathy is neither synonymous nor coincident with the clinical 
severity of eye disease (12). Several approaches have been proposed to evaluate disease 
activity in GO. Among them, Clinical Activity Score (CAS) (13) has been shown to be a 
useful method in everyday clinical practice.  
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Although the inflammation takes place in the retrobulbar space, changes in the anterior 
segment of the eye also appear in GO. Tears play an essential role in maintaining the 
homeostasis of the ocular surface. Cytokine release into tears is involved in the recruitment 
and activation of inflammatory cells. Alternations in the pattern of tear cytokine balance can 
be observed during the day (14) or by eye closure (15). Studies on tear cytokines have shown 
that many ocular or systemic diseases lead to changes in the cytokine profile of the tear film 
(16).  Changes in cytokine levels in human tears can be caused by seasonal allergic 
conjunctivitis (17), cystic fibrosis (18) and even anti-glaucoma eyedrops (19). Sjögren’s 
syndrome and keratoconjunctivtis sicca are also accompanied by alterations of cytokine 
balance in the tear fluid and conjunctival epithelium (20), and IL-6 and TNF-α levels are 
elevated in tears of patients with dry eye (21).  Passive cigarette smoke exposure leads to 
alterations of the tear film and increased tear inflammatory cytokine levels (22) . Similar 
changes in tear composition of healthy smokers and patients with GO have been reported (23). 
 Early studies reported abnormally high tear osmolarity and rapid tear film break up 
time in patients with GO (24). Alterations in tear film profile, low break up time and Rose 
Bengal staining in late GO indicate the presence of drying epithelial cells (25). Changes in 
tear protein profile by high-performance liquid chromatography (HPLC) have also been 
published, suggesting that GO has an effect on the lacrimal gland (26). Lacrimal gland 
enlargement was found in 22% of GO patients by orbital computed tomography (27). 
Expression of the TSH receptor on lacrimal gland acinar cells has also been reported. In GO 
Thyroid Stimulating Hormone (TSH) may bind to these cells causing lacrimal gland 
impairment (28). Also, lacrimal glands have been described as target organs for thyroid 
hormone (29). Probable involvement of the lacrimal gland as an area of immunological 
reaction in GO have been suggested based on octreotide scintigraphy (30, 31). Impression 
cytology findings also underline the ocular surface changes in GO (32). According to 
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proteomic analysis (biomarkers with a molecular weight between 3000 and 20 000 Da) the 
majority of tear proteins are downregulated in GO, with only few overexpressed proteins (33). 
Specific polymorphisms in proinflammatory cytokine genes (IL-12, Interferon γ (IFNγ), 
TNFα  and IL-1β) are associated with susceptibility to GO among Graves’ disease patients 
(34, 35). 
Plasminogen activator inhibitor-1 (PAI-1), besides being the inhibitor of fibrinolysis, 
also plays an important role in regulation of vascular function and tissue remodeling (36, 37). 
TNFα is an agonist for PAI-1 expression and the role of this cytokine in PAI-1 gene activation 
is well established (38). Increased PAI-1 activity has been found in the serum of Graves’ 
disease patients (39) . 
In the present study, we investigated the cytokines IL-1β, IL-6, IL-13, IL-17A, IL-18, 
TNF-α and the chemokine RANTES, as well as PAI-1 in tear samples of patients with 
Graves’ orbitopathy (GO), in patients with Graves’ disease without orbitopathy (GD) and in 
healthy controls.  
 
METHODS 
Tear samples were collected from 54 eyes of twenty seven patients with Graves’ 
orbitopathy (GO) (6 males, 21 females, age 43.4 ±15.2 years) and 18 eyes of nine Graves’ 
disease patients without orbitopathy (GD) (1 male, 8 females, age 46.8±11.7 years) according 
to standard criteria (40). Patients underwent careful detailed ophthalmological examination 
(slit lamp microscopy, corneal staining, Schirmer I test, tear film break up time (BUT), Hertel 
exophthalmometry, indirect ophthalmoscopy). Before tear collection, the anterior ocular 
status of each subject was carefully assessed: a slit-lamp under low illumination was used to 
avoid reflex tearing, while all other ophthalmological evaluations were performed after 
sample collection. Clinical Activity Score (CAS)(13) was obtained in each case. None of the 
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patients used any topical eye medications; only non-preserved artificial tears were allowed 
which could not be instilled on the morning of sample collection. Thyroid status including 
serum hormone levels (TSH, free T4, free T3, TSH receptor binding antibodies) were 
determined within a 5-day interval before or after tear collection using 
electrochemiluminescence immunoassay (TSH, FT3, FT4 assay by Elecsys/Cobas Roche 
Diagnostics GmbH, Mannheim, Germany). History of smoking and any significant general or 
ophthalmological disease were taken. The control group (C) consisted 24 eyes of twelve 
healthy volunteers (4 males, 8 females, age 38.6±13.8 yrs). All enrolled patients gave 
informed consent and the Institutional Review Board approved the study protocol in 
accordance with the 1989 Declaration of Helsinki. 
Tear samples were obtained by capillary flow with no nasal stimulation or previous 
installation of drugs or vital dyes, by the same examiner (BU). No anesthetic drops were 
instilled; samples were collected non-traumatically from the inferior meniscus without 
touching the cornea, conjunctiva or eyelids. The amount of the tear sample collected (µl), and 
the collection time (sec) were recorded. The samples were frozen without centrifugation 
within 15 minutes of collection and stored at –70°C until cytokine measurements were 
performed. Preliminary studies had demonstrated that centrifugation of the samples did not 
influence cytokine concentrations. 
Levels of cytokines were measured by a multiplex bead array method. Combined 
FlowCytomix™ Simplex Kits were used with an appropriate FlowCytomix Basic Kit 
according to the manufacturer’s instructions (Bender MedSystems GmbH, eBioscience 
Company, Vienna, Austria). Briefly, tear samples (in some cases diluted samples) or serial 
dilution of mixed cytokine standards were added to the wells of filter micro plates containing 
the fluorescent cytokine capture bead mixtures. Biotin conjugated anti-cytokine antibody 
mixtures were applied and the plates were incubated at room temperature for 2 hours 
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protected from light on a microplate shaker. The filter plates were washed using a 
MultiScreen HTS Vacuum Manifold (Millipore, Billerica, MA, USA). Phycoerythrin 
conjugated streptavidin solution was added to the samples and were further incubated for 1 
hour as described above. Plates were washed again, then 150 µl sample buffer was added to 
the wells and sample data were acquired by multiparameter flow cytometric analysis with a 
FACS Array cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA, USA).  
Data were analyzed with the BenderMedSystems FlowCytomix
TM
 Pro 2.4 software. 
During the preparation of the human cytokine standards, additional dilutions were applied to 
achieve higher sensitivity, and modified standard curves were generated during the analysis. 
Assay sensitivities were 4.2 pg/ml for IL-1β, 1.2 pg/ml for IL-6, 4.5 pg/ml for IL-13, 2.5 
pg/ml for IL-17A, 3.3 pg/ml for IL-18, 3.2 pg/ml TNF-α, 25 pg/ml for RANTES. and 13.5 
pg/ml for PAI-1. 
Tears were collected  from each eye for 2 minutes. For more precise evaluation we 
measured with a timer the exact collection time in seconds. The amount collected was also 
registered. The volume was calculated from the length of the tear column in the tube (100 mm 
length by 0.5 mm inner diameter capillary tubes were used) and was also checked when 
pipetting the samples for evaluation. We got the results of the flow cytometric assay in pg/μl 
for all cytokine concentrations. The result was multiplied with the volume of tear collected (μl) 
and divided by the collection time (sec).  
 
      Concentration of cytokine in tear sample x Volume of tear collected 
Release of cytokine =  ——————————————————————————  
          Collection time  
 
The 2 minutes cytokine release values (pg/2 min) were used for further statistical 
analysis.  
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Statistical analysis was carried out using the SAS for Windows 8.2 software. Hormone 
and cytokine levels in the three study groups (GO, GD and C) were compared by analysis of 
variance (ANOVA) with Duncan post hoc testing. Both cytokine levels and cytokine releases 
have been correlated with patient age, clinical parameters (CAS, Schirmer I test), smoking 
(number of cigarettes per day) by Spearman correlation analysis. 
 
RESULTS 
Medians and upper and lower quartiles of both concentrations and release values of 
cytokines in each patient group are shown in Table 1. As release values reflect the real 
cytokine production, these were used for further analysis.  
 ANOVA analysis showed significant difference between the cytokine release values 
measured in the GO and C groups. The release of IL-1β, IL- 6, IL- 13, IL-17A, IL-18, TNF-α 
and RANTES were significantly higher in the GO group as compared to the control group 
(p<0.05). No significant difference was found between GD and group C in the release of the 
cytokines tested. Also, no statistically significant differences were found between the cytokine 
release into the tears of GO and GD patients regarding any cytokine tested, although release 
values tended to be higher in the GO group, i.e., the values of GD patients were intermediate 
between the GO and the control groups in the case of all cytokines (Fig. 1). Release of PAI-1 
into tears was significantly higher in the GO group compared to GD patients, and both GO 
and GD patients’ PAI-1 release values were significantly higher than the control group’s 
(Table 1).  
Positive correlation were found between the release of all tested cytokines and the 
secretion of PAI-1 in tears (IL-1β: r=0.23 p=0.002, IL- 6: r=0.31 p=0.001, IL- 13: r=0.30 
p=0.001, IL-17A: r=0.23 p=0.015, IL-18: r=0.24 p=0.012, TNF-α: r=0.29 p=0.002 and  
RANTES: r=0.23 p=0.014).  
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 We have found strong correlation between the release of all examined cytokines, the 
correlation coefficient ranging between 0.66 and 0.97 (p<0.01 in all comparisons).  The 
strongest correlations have been detected between the release of IL-1 and RANTES  (r= 0.96 
p<0.001), as well as IL-1 and the other members of the IL-1 family (IL-18: r=0.97, p<0.001, 
IL-17A: r=0.89, p<0.001). 
 Except for IL-17A, we found no correlation between tear cytokine concentrations and 
age; for IL-17A, the correlation was negative (r= -0.21, p<0.05). Also, a weak negative 
correlation was found between age and PAI-1 release (r= -0.24 p<0.05). ANOVA analysis 
showed no significant difference between the GO and GD groups regarding serum TSH, free 
thyroid hormone (fT4, fT3) and TSH receptor antibody levels. 
We found significant difference between the left and right eyes in the release of all 
examined cytokines by both paired T test and Wilcoxon Matched Pairs Test (p<0.05 for all 
examined cytokines, and p<0.001 for Il-6, IL-18 and PAI-1). 
Ophthalmological evaluation of GO patients showed the signs of ocular surface drying. 
However, no corneal pathology (fluorescein staining, erosion or ulceration) was present at the 
time of sample collection. Schirmer I test showed a mean lacrimal secretory capacity of 13.94 
± 10.07 mm in the GO group, 14.22 ± 8.04 mm in the GD group and 19.37 ± 9.17 mm in the 
C group; differences between the GO and GD patient groups were not statistically significant, 
however, both were significantly lower than the control group. The mean BUT was 3.58 ± 
2.35 sec in the GO group (range from 4 to 32 sec in healthy adults (41)). The CAS in the GO 
group was 3.82  ± 2.0. 
Positive correlations were found between Schirmer I test and the release of all tested 
cytokines in the control group (IL-1 beta: r=0.53, p=0.002, IL-6: r=0.46, p=0.01, IL-13: 
r=0.50 p=0.005, IL-17A: r=0.54 p=0.002, IL-18: r=0.54 p=0.002, TNF alfa: r=0.52 p=0.003 
and RANTES: r=0.56 p=0.001). Similarly, positive correlation were found between Schirmer 
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I test and the release of PAI-1 in the control group (r= 0.40 p=0.002). However, none of the 
cytokine release values were correlated with the lacrimal secretory capacity (Schirmer I test) 
and the BUT in the GO or GD group. We found a weak positive correlation between Schirmer 
I test and PAI-1 relese in the GO group (r=0.28 p=0.04) but not in the GD group.   
In the GO group, a positive correlation was found between IL-6 release and the CAS 
(r=0.27, p <0.05) as well as between IL- 6 release and the degree of eyeball protrusion (mm in 
Hertel exophthalmometer) (r=0.34, p<0.05). Also positive correlation was found between 
PAI-1 release and the CAS (r=0.24, p=0.03).  
 Among the twenty-seven GO patients 10 were former or current smokers (cumulative 
number of cigarettes smoked 78309±53631 consuming an average of 14.73±6.61 
cigarettes/day), while among the nine GD patients without orbitopathy 6 were former or 
current smokers (cumulative number of cigarettes smoked 85166±101169 with an average of 
11.67±10.81 cigarettes/day). In the control group, no patient was a current or former smoker. 
We found no connection between tear cytokine levels or release values and smoking (by the 
number of cigarettes per day, or using digitomized variables yes/no). When the cytokine 
release values were analyzed in all patients irrespective of the presence of GO, as well as in 
controls, and were regrouped according to smoking history, no differences were found in the 
release of any examined cytokine.    
 
DISCUSSION 
Tears play an essential role in maintaining the homeostasis of the ocular surface. Many 
ocular or systemic diseases have been shown to lead to changes in the cytokine profile of the 
tear film (16-21). In this study, we monitored the level of a selected set of cytokines that 
included TNF-α, IL-1β, IL-6, IL-18, IL-17A, IL-13, the chemokine RANTES and PAI-1 in 
tear samples of Graves’ patients with and without orbitopathy. 
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The multiplex bead array, which was used in the present series of experiments, is a 
highly sensitive technique which enabled us to carry out parallel measurements of multiple 
cytokines by flow citometry in a small amount of tear. In contrast to previous results showing 
higher tissue concentrations of TNF-α, IL-1β and IL-6 (42) as well as serum concentrations of 
IL-6 (43) and PAI-1 in Graves’ disease when compared to healthy controls, we found no 
significant difference between the GD and control groups in the release of tear cytokines. 
These findings indicate that tear cytokines are regulated differently, and the appearance of 
proinflammatory cytokines in the tears of patients with GO, but not in those with GD without 
orbitopathy, is not the result of the thyroid disease but the orbitopathy itself. Sources of 
cytokines and chemokines in tears may include the main and accessory lacrimal glands, the 
corneal and conjunctival fibroblasts and the immunovigilant cells normally present in the 
ocular surface (44). Previous studies have shown that the lacrimal gland is involved in GO 
and that it could also be an area of immunological reaction (26-31). Reports have been 
published on the early conjunctival involvement in Graves’ disease, suggesting that the ocular 
surface impairment in GO is not only a consequence of mechanical events but ocular surface 
tissues are direct targets for autoantibodies in GD (45). Conjunctival and episcleral 
inflammation can occur before the classic signs of orbitopathy and the pathogenesis is 
assumed to be similar to that involved in the extraocular muscle inflammation and 
lymphocytic infiltration in GO (46). 
In our study, we found a significant increase of cytokine release of TNF-α , IL-1β, IL- 
6, IL-18, IL-17A, IL-13 and RANTES in the tears of the GO patient group as compared to 
controls. The importance of the macrophage-derived cytokines TNF-α and  IL-1β in GO have 
been described (5, 6)  and were shown to stimulate ICAM-1 expression and GAG production 
by orbital fibroblasts (9). High release of TNF-α and IL-1β into tears of patients with GO may 
indicate their presence not only in the retrobulbar connective tissue, but also in the lacrimal 
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gland and ocular surface. IL-1β-activated fibroblasts express high levels of T cell 
chemoattractants such as RANTES (10) which may explain the increased release of RANTES 
in tears of patients with GO. A strong correlation between the releases of IL-1 and RANTES 
as well as IL-1 and IL-18 was also demonstrated in our study. Increased IL-18 serum levels 
in both GO and GD individuals have also been observed by others (47). In our study, however, 
elevated release of IL-18 could be measured only in the tears of GO patients, but not in the 
GD or the control group.  
As we found a more than twofold IL-6 release in the tears of the GO group as 
compared to controls, we theorize that elevated IL-6 release in tears might be an indicator of 
disease activity. This assumption is further supported by the fact that in the GO group, we 
found a positive correlation between IL-6 release and the CAS. A positive correlation was 
also found between IL-6 release and the degree of eyeball protrusion.  
Others found serum IL-6 levels to be elevated in hyperthyroid GD and GO (43). 
However, the serum levels are influenced by additional factors, such as thyroid status and 
therapy, which limits its use as an activity indicator in GO (8). Elevation of IL-6 tear 
concentration has also been described in dry eye and dysfunctional tear syndrome (48). 
Although GO is accompanied by dry eye, including the tear deficient form (non-Sjögren type 
dry eye) (24) and the evaporative form due to exophthalmos (25), GO is not associated with 
Sjögren’s syndrome.  IL-6 levels in tears of Sjögren’s syndrome patients is higher than in 
non-Sjögren type tear deficient dry eye (21). To evaluate lacrimal secretory capacity we 
performed the Schirmer I test. In both the GO and GD groups tear secretion was diminished. 
Our findings correspond to the results of Gurdal et al. (49) who found significantly lower 
Schirmer test readings among Graves’ disease patients with and without orbitopathy than in 
controls. The authors suggested that ocular surface damage and accompanying surface 
inflammation may precede the development of classic GO symptoms (49). However, elevated 
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proinflammatory cytokine secretion into tears may also be the consequence of ocular surface 
inflammation, even when inflammation cannot be detected with clinical examination methods, 
and thus considered as an early sign for ocular involvement in GD. We found a positive 
correlation between Schirmer I test and all the cytokine releases tested, includig IL-6, in the 
control group. However, neither a positive or a negative correlation between Schirmer I test 
and cytokine releases was detected in the GO and GD groups. This important finding supports 
the notion that increased cytokine releases are not the result of decreased lacrimal secretory 
capacity. Instead, cytokine release and lacrimal secretory capacity are two distinct 
mechanisms. The lacrimal glands’ tear secretory function is damaged in GO and GD, while 
cytokine release is elevated as part of the immune process.  
IL-13 is a Th2 cytokine that plays a role in IgE-mediated immunity. In chronic ocular 
inflammation, where keratopathy is present, an increased level of IL-13 can be observed 
together with eotaxin-1 (50). About 30% of patients with Graves’ disease have increased 
concentrations of IgE in their sera, and in one third of patients with hyperthyroid Graves’ 
disease, Th2 cells are stimulated and secrete excess amounts of IL-13 (51). The elevated 
release of IL-13 in tears of patients with GO might be related to high serum IgE, or may be 
simply an indicator of ocular surface reparation of clinically non-detectable exposure 
keratopathy. The latter assumption is supported by the lack of fluorescein staining during slit 
lamp examination in any of our patients. 
We believe that, to some extent, the ocular surface including the conjunctiva, is 
involved in the autoimmune process in patients with Graves' disease. Cytokine release values 
of the GO group were higher only when compared to the tears of healthy controls, while 
cytokine relases of the GD group did not differ from either the GO or the control group. 
However, the release values tended to be highest in the GO group, followed by the GD and C 
groups (Fig. 1). We assume that this might be the result of the clinically non detectable orbital 
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involvement of patients in the GD group. We speculate that there are GD patients who fail to  
present with clinically detectable orbitopathy, although their orbital connective tissues and 
lacrimal glands are already affected. Subclinical eye involvement is common in the orbits: 
extraocular muscle enlargement have been found in nearly 70% of adult patients with Graves’ 
hyperthyroidism by orbital imaging (52). Subclinical eye involvement in GD might remain 
silent but may proceed to manifest GO resulting in continuous changes in the orbital 
structures that are represented in tears. Thus, tear cytokine release in these GD patients tends 
to be higher than in controls but remains below the values of GO patients, representing the 
possible manifestation of a subclinical disease. 
PAI-1 release was significantly higher in the GO group than in the GD group, and was 
higher in both the GO and GD groups than in group C (Table 1).  Others have reported higher 
PAI-1 concentrations in the plasma of GD patients compared to controls (39). In our series, 
the only examined protein that showed a statistically increased release in GO patients 
compared to GD patients was PAI-1. The tissue remodeling function of PAI-1 (36, 37) may 
account for the difference between the GD and GO groups in favour of the latter. The role of 
PAI-1 in normal control tears is the maintenance of ocular surface integrity (53). Strong 
positive correlations have been found between the release of all examined cytokines and the 
release of PAI-1 in tears, supporting the previously described role of cytokines in PAI-1 gene 
activation (38). Both IL-6 and PAI-1 releases correlated with CAS in our patients. PAI-1 
release in tears may either be an indicator of disease activity in GO or simply the result of 
anterior segment changes in GO, which are also represented in CAS. However, unlike IL-6 
release, PAI-I does not seem to be a practical marker of disease activity in GO.  
Passive cigarette smoke exposure leads to alterations in the tear film and increase in 
inflammatory cytokine levels (22). Similar changes in the tear composition of healthy 
smokers and patients with GO have been reported (23). We found no correlation between tear 
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cytokine levels or releases and smoking history. Previously, Salvi at al. described similar 
findings. These being the lack of smoking-induced changes in serum IL-6, TNF-α and IL-1β 
concentrations (8). 
We are not aware of any previous studies on cytokines and PAI-1 in tears of patients 
with Graves’ disease. We are the first to show that there is a correlation between disease 
activity and IL-6 release in tears in GO. Our findings demonstrate that Graves’ orbitopathy 
results in changes in the cytokine profile of the tear film. We detected an elevation of the pro-
inflammatory cytokines TNF-α, IL-1β, IL-6, IL-18, IL-17A, IL-13 and RANTES in the tears 
of patients with GO. Correlations between IL-6 release in tears and CAS as well as the degree 
of eyeball protrusion were also detected. We propose that high IL-6 release in tears may serve 
as a useful indicator of disease activity in GO. 
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 Table 1. Concentrations and release values of tear cytokines and PAI-1 
 
    Release Concentration 
  
  Median 
Lower 
quartile 
Upper 
quartile Median 
Lower 
quartile Upper quartile 
IL-1 β 
C 9,58 4,47 14,04 701,02 403,99 974,41 
GD 16,13 5,58 19,51 797,83 384,2 1124,57 
GO 20,67* 6,04 32,32 1083,54 585,47 1263,51 
IL-6 
C 1,61 0,72 2,01 119,7 66,38 152,12 
GD 2,62 1,13 3,98 133,03 90,5 166,99 
GO 4,07* 0,92 6,65 204,19 100,95 243,56 
IL-13 
C 5,25 2,63 7,19 424,45 220,14 515,85 
GD 7,73 3,38 10,63 444,34 298,83 545,33 
GO 9,31* 4,29 13,38 547,28 317,01 692,33 
IL-17A 
C 3,39 0,32 4,97 179,21 70,27 258,44 
GD 5,52 0,67 7,13 257,57 78,05 299,68 
GO 8,39* 1,23 12,22 386,34 95,71 455,27 
TNF-α  
C 3,97 1,42 6,18 264,31 168,34 307,62 
GD 6,58 2,09 8,98 332,89 167,21 418,03 
GO 8,58* 2,11 12,44 444,31 178,06 535,31 
RANTES 
C 6,4 1,38 9,69 379,41 246,44 479,59 
GD 9,74 2,83 15,08 496,96 267,57 663,63 
GO 12,34* 3,69 19,97 648,81 322,94 740,32 
IL-18 
C 29,96 9,91 49,77 1855,66 1158,36 2581,87 
GD 50,83 14,67 70,82 2480,56 1213,82 3553,84 
GO 66,28* 15,79 100,87 3411,37 1722,58 3913,63 
PAI-1  
C 6,87 3,025 9,9 366,67 227,89 687,5 
GD 9,81* 1,93 15,95 463,89* 210,07 623,33 
GO 11,73** 1,38 22 555,32** 265,83 673,75 
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Table and figure legends: 
 
Table 1. Concentrations and release values of tear cytokines and PAI-1 
The concentrations and release values are expressed as pg/ml and pg/2min, respectively.  
Values marked with * are significantly different form control (p<0.05). ** shows that PAI 
release and concentration are significantly higher in the GO group compared to the GD group. 
Values were compared by analysis of variance (ANOVA) with Duncan post hoc testing. 
GO - Graves’ orbitopathy, GD – Graves’ disease without orbitopathy, C - Controls 
 
 
Figure 1. Median of tear cytokine and PAI-1 release values  into tears (pg/2min)     
Cytokine releases marked with  *are significantly different form controls (p<0.05). GD 
patients were intermediate between the GO and the control groups in the case of all cytokines. 
This also applies to IL-18 (not shown in the figure).  
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